Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. (NYSE: LH) is frequently in the news as a global provider of innovative and comprehensive laboratory services. Company announcements highlight activities across diagnostics, oncology, neurology, consumer testing and biopharma laboratory services, giving investors and healthcare professionals insight into how Labcorp is evolving its business and scientific capabilities.
Recent press releases have covered topics such as quarterly financial results, updated full-year guidance and cash dividends on Labcorp’s common stock. These items show how the company communicates its financial performance, capital allocation decisions and participation in investor conferences and healthcare industry events.
Labcorp’s news flow also emphasizes developments in specialty testing. The company has reported on the expansion of its Plasma Detect molecular residual disease portfolio for monitoring recurrence risk in certain breast, lung and colon cancers, and on clinical studies featuring its MRD technology in journals such as Nature Medicine and Clinical Cancer Research. In neurology, Labcorp has announced plans to offer the Elecsys pTau181 blood test, cleared by the U.S. Food and Drug Administration to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline.
Other news items describe collaborations and transactions, including agreements to acquire select outreach laboratory assets from health systems, the sale of select early development medical device testing assets to NAMSA, and partnerships that expand access to at-home testing through Labcorp OnDemand. Governance updates, such as board appointments and executive retirements, are also disclosed through company news.
This page aggregates these types of updates, allowing readers to follow Labcorp’s announcements on clinical testing innovations, oncology and neurology offerings, consumer-focused services, strategic partnerships, financial results and corporate governance.
Knoa Pharma (V) began operations on May 1, 2026 as a public health–focused pharmaceutical company wholly owned by the not‑for‑profit Knoa Foundation (a 501(c)(4)).
The company will manufacture existing medicines, including opioid analgesics, under a strict operating injunction with independent monitoring, will not promote opioid products, and will use value generated to fund opioid abatement and no‑profit access to overdose reversal and OUD treatments.
Labcorp (NYSE: LH) reported Q1 2026 revenue of $3.54B (up 5.8%) and diluted EPS of $3.35 (up 32.8%). Adjusted EPS was $4.25 (up 10.6%). Operating income rose to $380.8M; operating margin improved 100 bps. Free cash flow turned positive to $70.5M. Labcorp raised 2026 enterprise revenue guidance to +5.0%–6.1% and adjusted EPS to $17.70–$18.35 (midpoint $18.03).
The company cited acquisitions, diagnostics and biopharma growth, technology collaborations, $202.2M acquisitions, $98.0M buybacks, and a $0.72 quarterly dividend.
Labcorp (NYSE: LH) announced nationwide availability of Agilent's PD-L1 IHC 22C3 pharmDx on April 22, 2026, the only FDA‑approved companion diagnostic to identify patients with platinum‑resistant ovarian cancer eligible for Merck's KEYTRUDA therapies.
Labcorp joined Agilent's Early Validation Program to prepare standardized training and rapid rollout following the FDA's February approvals of KEYTRUDA and KEYTRUDA QLEX alongside the diagnostic.
Labcorp (NYSE: LH) launched the Labcorp Fentanyl Urine Visual Test, the first FDA-cleared rapid fentanyl urine test of its kind manufactured in the United States. The test delivers results in 10 minutes, detects norfentanyl with up to a 48-hour window, and is for CLIA-certified professional use.
Results are intended as preliminary screening and should be confirmed by laboratory methods. The test is available through Labcorp Point of Care (formerly MEDTOX Diagnostics), with product branding transitioning during 2026.
Labcorp (NYSE: LH) launched an AI-powered real-world data platform with AWS and Datavant to speed Alzheimer's research, using deidentified laboratory, genomic and claims data. The platform aims to compress months of data preparation into minutes, completes initial validation in spring 2026, and will expand through 2026 to additional disease areas.
It supports cohort identification, treatment-effectiveness analysis, and trial recruitment using Amazon Bedrock and SageMaker and privacy-preserving connectivity.
Labcorp (NYSE: LH) and Children's Hospital of Philadelphia announced a strategic collaboration on April 13, 2026 to speed discovery, development and national availability of specialized pediatric diagnostics.
The partnership creates a joint pediatric diagnostics innovation pipeline to develop age-appropriate tests across oncology, metabolic disease, autoimmune conditions and rare disorders and to expand nationwide access through Labcorp's laboratory network.
Labcorp (NYSE: LH) announced a quarterly cash dividend of $0.72 per share on April 9, 2026. The dividend is payable on June 11, 2026 to holders of record at the close of business on May 29, 2026.
This returns cash to shareholders and sets clear payment and record dates for investors.
Labcorp (NYSE: LH) will report first-quarter 2026 financial results before the market opens on April 30, 2026. A live webcast will begin at 9:00 a.m. ET the same day to discuss results. The earnings release and financial information will be posted on the investor relations website.
A replay will be posted approximately two hours after the live event and will remain available for one year on the site's News & Events section.
Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.
Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).
Labcorp (NYSE: LH) expanded its collaboration with PathAI to deploy AISight Dx, an FDA-cleared digital pathology platform, across Labcorp's national anatomic pathology labs and hospital collaborations on Feb. 23, 2026. The cloud-based system enables fully digital workflows, AI-powered image analysis, secure storage and connectivity.
According to the company, deployment aims to scale digital slide review, improve turnaround times, enhance collaboration and support Labcorp's precision medicine products, building on a 2019 strategic investment in PathAI and prior AI-driven clinical trial support.